Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ODC1 | P11926 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198049 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP4F2CYP4A11CPB2PKM | |
| SCHEMBL6593255 | 0.94 | CYP4F2 (0.47) | CYP1A2CYP4F2CYP4A11CPB2PKM | |
| SCHEMBL26986116 | 0.86 | CYP4F2 (0.46) | CYP1A2CYP4F2CYP4A11PKMTHRB | |
| SCHEMBL22519815 | 0.82 | CYP4F2 (0.65) | CYP1A2CYP4F2CYP4A11CPB2PKM | |
| SCHEMBL25169854 | 0.82 | CYP1A2 (0.48) | CYP1A2CYP4F2CYP4A11CPB2PKM | |
| SCHEMBL28797858 | 0.82 | CYP4F2 (0.44) | CYP1A2CYP4F2CYP4A11PKMTHRB | |
| SCHEMBL6589766 | 0.82 | CYP4F2 (0.44) | CYP1A2CYP4F2CYP4A11PKMTHRB | |
| SCHEMBL8979106 | 0.80 | MEN1 (0.53) | CYP1A2CYP4F2CYP4A11CPB2PKM | |
| SCHEMBL6595080 | 0.80 | ODC1 (0.38) | CYP1A2THRBKMT2AMAPTODC1 | |
| SCHEMBL7203818 | 0.80 | ODC1 (0.38) | CYP1A2THRBKMT2AMAPTODC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | CYP1A2 2332/4885CYP4F2 460/4885CYP4A11 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.